Event overview:

Patient centric drug product design provides an opportunity to increase safety and effectiveness.  Fundamental understanding of the relationship between drug concentration and pharmacological effect allows definition of a target exposure profile. Once defined for a given disease target, the feasibility of achieving the target exposure profile can be assessed through molecular and/or formulation design, leading to selection of candidate drugs with the right balance of pharmacological, safety and pharmaceutical/ADME properties. This session will include 2 talks and a panel discussion centering on the application of PKPD modelling and in-vitro safety screening in discovery and early clinical development.

Chair:
Linette Ruston
Senior Principal Scientist
ADME at Seda Pharmaceutical Development Services

Speakers :

Jake Dickinson
Senior Modeller
Seda Pharmaceutical Development Services
Title   “Early understanding of PK/PD: setting up success in development?”

Michael Morton
Co-founder of ApconiX
Title  “Addressing seizure liability in discovery”